Xencor Inc. (NASDAQ:XNCR)’s share price shot up 2.3% on Friday . The stock traded as high as $18.46 and last traded at $18.38, with a volume of 300,128 shares trading hands. The stock had previously closed at $17.96.

Several research firms have recently weighed in on XNCR. Wedbush reaffirmed an “outperform” rating and issued a $27.00 price objective on shares of Xencor in a research note on Tuesday, June 28th. Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of Xencor in a research note on Wednesday, June 29th. Canaccord Genuity reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Xencor in a research note on Monday, April 4th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Xencor in a research note on Monday, May 2nd. Finally, TheStreet raised Xencor from a “sell” rating to a “hold” rating in a research note on Monday, April 25th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $23.29.

The company has a 50-day moving average of $15.75 and a 200-day moving average of $13.24. The company’s market cap is $748.89 million.

Xencor (NASDAQ:XNCR) last announced its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. The company had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $3.50 million. On average, equities research analysts predict that Xencor Inc. will post ($0.77) earnings per share for the current fiscal year.

In related news, CEO Bassil I. Dahiyat sold 45,886 shares of the company’s stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $13.00, for a total transaction of $596,518.00. Following the transaction, the chief executive officer now directly owns 358,186 shares of the company’s stock, valued at $4,656,418. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.